Tejaswini Kulkarni

#PulmCC Physician Scientist @uabmedicine| Director @ UAB-ILD program #curePF|@HarvardChanSPH alum|Wife and Triplet Mom #womeninmedicine| Tweets are mine.

[Samarth Kulkarni @CrisprSam]

This is a wonderful recognition for CRISPR! Congrats to all the innovators for all these groundbreaking inventions.

[CHEST @accpchest]

#CHEST2024 Recap: Experts discussed how to evaluate and manage clinical worsening in patients with PH-ILD.

Read more in CHEST Daily News: https://t.co/vPtkI2ZPNZ

[Tejaswini Kulkarni @tkulkarn1]

Our @AnnalsATS paper exploring factors associated with persistence of antifibrotic therapies among patients with IPF enrolled in @PFFORG registry is now in press; underscores the importance of addressing mental health. #curePF @ahajaricase @UABPulmonary

[Tejaswini Kulkarni @tkulkarn1]

@KaminskiMed 🙏🏼

[Naftali Kaminski @KaminskiMed]

Great talk at #ICLAF2024 by Prof Kulkarni
on phase 3 clinical trials in Pulmonary Fibrosis - provides insight on failure - hope for success
👏🏼👏🏼👏🏼@tkulkarn1 👏🏼👏🏼🙏🏼

[Tejaswini Kulkarni @tkulkarn1]

@KaminskiMed Fantastic talk and tribute to Andy Tager! #ICLAF2024 #curePF

[Tejaswini Kulkarni @tkulkarn1]

Lessons learnt, cautious optimism and moving forward in clinical trials in ILD - #ICLAF2024

[Tejaswini Kulkarni @tkulkarn1]

Excellent panel discussing disparities and environmental exposures in ILDs - #ICLAF2024 #CurePF

[Tejaswini Kulkarni @tkulkarn1]

#ICLAF2024 kicking off with patient experience session and looking forward to 5 days of advances towards #curePF

[Claudia Tejera, MD @clautejera]

Excellent discussion on early initiation of anti-fibrotic therapy in Non-IPF fibrotic lung disease, led by @tkulkarn1 and Dr. Danoff.

Should our primary emphasis be on enhancing QoL? Active involvement of patients in decision-making processes is key!

#CHEST2024 #CHESTTrainees

[ATS Clinical Problems Assembly @ATSCPAssembly]

Join us for journal club Thursday, October 3rd, 10 am EST on "Microscopic Small Airway Abnormalities Identified in Early Idiopathic Pulmonary Fibrosis In Vivo Using Endobronchial Optical Coherence Tomography"

Register here: https://t.co/GsNPOwtlOE

[Naftali Kaminski @KaminskiMed]

Wow! Boehringer-Ingelheim announces that Nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER™-IPF study - a decade after the first positive phase III trials for IPF. Cannot wait to see the full results but this EXCITING !!!
#CureIPF
https://t.co/TvI1P6uWpc

[ThoraxBMJ @ThoraxBMJ]

To commemorate Pulmonary Fibrosis Awareness Month, we will be sharing brilliant Pulmonary Fibrosis research from Thorax over the last year #CurePF

This paper highlights the innovative REMAP-ILD concept for drug development in fibrotic ILDs @leticiakawano @IPFdoc
https://t.co/DLeavwNj8Q

[Tejaswini Kulkarni @tkulkarn1]

@IQuEStHouston @BhavikaKaulMD Congratulations @BhavikaKaulMD

[Tejaswini Kulkarni @tkulkarn1]

In clinical practice,there are often questions about approach to positive antibodies in the absence clinical signs of SARD. This study shows that IPF disease course and response to Pirfenidone did not differ by autoantibody status #CurePF @cnewto

[Human Immunology News @humanimmunenews]

Dr. Tejaswini Kulkarni (@tkulkarn1) and researchers at @UABPulmonary evaluated the association of antinuclear #antibodies, #rheumatoid factor, and 💊 treatment outcomes of patients with #IPF from the 🩺 Phase III ASCEND trial.

@Pulmonary_Ther | https://t.co/yf97ubG5IJ

[David Zhang @DavidZhangMD]

Telomere length testing is a readily available clinical test for precision management of ILD. We describe the clinical impact of TL testing in ILD clinic including impact on pharmacologic management and genetic testing @journal_CHEST

https://t.co/SUOMlFwZmX

[Tejaswini Kulkarni @tkulkarn1]

@drdayjee @UChicagoMed @UChicagoPCCM @UChicago @Y_Gilad @HGEN_UChicago @UCM_HDS @WF_Parker @michaelwd @FutureDocs @UChiPritzker Fantastic- congratulations 😀

[Tejaswini Kulkarni @tkulkarn1]

A great discussion on the methodology of these upcoming guidelines and key take away points on management of patients with SARD-ILD - #curePF #CHEST_ILDTx @accpchest @ATSCPAssembly @PFFORG

[CHEST @accpchest]

A Review of ACR/CHEST Clinical Practice Guidelines on Treatment of ILD With Systemic Autoimmune Rheumatic Diseases

Watch the full webinar by the Diffuse Lung Disease and Lung Transplant Network: https://t.co/Ggv4IpaTjc
#MedEd #MedTwitter #CHEST_ILDTx

[Deji Adegunsoye, MD, PhD @drdayjee]

Prof. Athol Wells presents elegant data from a recent multinational Delphi consensus that:

• Progression of ILD is progression irrespective of time since diagnosis

•“despite usual management” should be included in PPF definition

Important for future PPF guidelines.
#ATS2024

[Tejaswini Kulkarni @tkulkarn1]

@KaminskiMed @IPFdoc @KerriBerriKerri @TobyMMaher @drdayjee @ahajaricase @dantinozerkis @DoctorSwig @leticiakawano @ericafarrandMD Not enough but more to follow up on this topic!